Amarin Corp Plc (AMRN)

[rfj1862]

Adding a new therapeutic agent which is a novel way to approach a well understood disease is different than adding a new diuretic to treat a disease where everyone understands diuretics are beneficial.

That's a good point and you may be right for cardiovascular medicine.

In cancer (which is what I know best these days; I stopped working on Lipitor when it went off patent) it is pretty routine to add novel MOA drugs to standard of care before they ever get approval for a specific indication.